We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis.
- Authors
Li, Sijia; Chen, Xueqin; Hu, Penghua; Wu, Suijing; Ma, Jianchao; Li, Zhuo; Wu, Xiuchuan; Wen, Feng; Fu, Xia; Feng, Zhonglin; Tao, Yiming; Li, Bohou; Fu, Lei; Huang, Renwei; He, Chaosheng; Shi, Wei; Liang, Xinling; Liu, Shuangxin
- Abstract
Anemia is a common complication of chronic kidney disease (CKD). Recombinant human erythropoietin (rHu-EPO) is used extensively in patients with CKD. However, anti-erythropoietin (anti-EPO) antibody has been reported during rHu-EPO treatment, which causes pure red cell aplasia (PRCA). We presented a case of 75-year-old man, who underwent hemodialysis for 2 years. He developed PRCA during rHu-EPO treatment. The rHu-EPO was immediately discontinued, and the patient was given roxadustat treatment. After 6 months of roxadustat treatment, the anti-EPO antibody was disappeared, and hemoglobin recovered normal range. The results suggest that roxadustat can be used to treat patients with anti-EPO antibody-mediated PRCA without immunosuppressive therapy.
- Subjects
PURE red cell aplasia; HEMODIALYSIS patients; ERYTHROPOIETIN; RECOMBINANT erythropoietin; CHRONIC kidney failure
- Publication
Blood Purification, 2022, Vol 51, Issue 2, p189
- ISSN
0253-5068
- Publication type
Article
- DOI
10.1159/000513423